Diversified Healthcare Trust (DHC) Financials

Diversified Healthcare Trust (NASDAQ: DHC) remains a financially stressed real estate investment trust, but its latest quarter showed a few signs of improvement in cash generation even as profitability stayed deeply negative. Over the past four years, DHC has faced declining cash balances, persistent losses, heavy debt, and recurring impairment/restructuring charges.

Key takeaways from the recent trend:

• Q1 2026 operating cash flow turned positive at $8.3 million, a meaningful improvement from -$20.1 million in Q4 2025 and -$49.3 million in Q3 2025.
• The company ended Q1 2026 with $121.8 million in cash and equivalents, plus $18.1 million of restricted cash, giving it a reasonable near-term liquidity cushion.
• Investing activities provided $13.6 million of cash in Q1 2026, helped by property sales and investment maturities, which supported the quarter’s cash balance.
• DHC’s Q1 2026 net change in cash was +$18.1 million, a clear reversal from the prior quarter’s cash burn.
• Revenue has been relatively stable over the last year, staying in the $366 million to $389 million range on a quarterly basis.
• Diluted shares outstanding have been fairly stable, suggesting limited dilution pressure recently.
• DHC continues to report very large noncash depreciation and amortization expenses, which are common for healthcare real estate but make GAAP earnings look weaker than cash flow.
• The company remains unprofitable, with Q1 2026 net loss of $43.3 million, following a $21.2 million loss in Q4 2025 and a $164.0 million loss in Q3 2025.
• Operating performance is still weak: Q1 2026 operating income was -$4.7 million, while SG&A expense alone was $304.6 million.
• Debt remains very high at $2.40 billion in long-term debt in Q1 2026, against $1.62 billion in common equity.

Longer-term trend: DHC’s revenue has held up better than its earnings. Quarterly revenue has generally hovered in the mid-$300 millions since 2023, but expenses, interest costs, and periodic impairment charges have kept the company in the red. Interest expense has remained a major burden, often running between roughly $37 million and $87 million per quarter.

Balance sheet trend: The balance sheet has improved from a liquidity standpoint versus the worst points in 2024 and 2025, when cash balances were higher but operating cash flow was inconsistent and debt levels were still heavy. In Q1 2026, cash dropped to about $121.8 million from $201.4 million in Q3 2025, but the company still appears to have adequate short-term liquidity. The bigger concern is leverage, not immediate current liabilities, which were reported at zero in the available data.

Bottom line: DHC is showing some improvement in cash generation, but it is not yet a turnaround story on the income statement. For retail investors, the stock still looks like a high-risk REIT with limited earnings power, significant debt, and dependence on asset sales and financing flexibility to support the business.